The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Rocket Pharmaceuticals announced a restructuring that will include layoffs affecting 30% of its employees. The company is ...